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Abstract
Purpose This review aims to discuss the methodological
aspects of dedicated molecular breast imaging (MBI) using
99mTc-sestamibi as radiotracer to guide biopsy of occult or
unclear breast lesions on mammography (MG) and ultra-
sound (US) that are suspicious on MBI (BI-RADS criteria
4 and 5), including its advantages, limitations and future
clinical applications.
Methods Literature search was performed using the
PubMed/MEDLINE database and ‘‘99mTc-sestamibi’’,
‘‘biopsy’’ and ‘‘breast cancer’’ as keywords. The search was
restricted to English language.
Results There are few studies on 99mTc-sestamibi guided
biopsy methods; to our knowledge, no full studies have yet
been reported on clinical validation of this new biopsy
procedure. This review describes technical aspects of
99mTc-sestamibi guided biopsy and discusses the advan-
tages and limitations of this procedure in comparison with
MG, US and MRI-guided biopsy.
Conclusions MBI-guided biopsy appears to be a comple-
mentary modality and is principally indicated in the case of
occult or unclear breast lesions on MG/US, that are sus-
picious on MBI. The future indication is in targeted biop-
sies in patients with large heterogeneous tumours. Further
studies are needed to define the accuracy of this biopsy
procedure.
Keywords Molecular breast Imaging  Breast-specific c-
imaging  99mTc-sestamibi  Radioguided-biopsy  Breast
cancer
Introduction
Breast cancer (BC) is the most common cancer type in
women with an estimated 246.660 new cases and 40.450
deaths in the United States, in 2016 [1]. Mammography
(MG) is the imaging modality of reference in screening and
diagnosis of BC [2]. However, MG has an overall sensi-
tivity of 78 %, decreasing to 48–64 % in women with
dense breasts [3]. Ultrasonography (US) is the most com-
mon adjunct imaging modality, improving the sensitivity to
78 % when used together with MG in women with dense
breasts [4]. However, breast US is associated with a higher
callback rate and false-positive biopsy rate [5]. Due to the
limitations of both modalities, magnetic resonance imaging
(MRI) may be used as an adjunct modality. MRI is, for
example, recommended as an adjuvant screening modality
in high-risk women [6], increasing the detection rate to 9.5
per 1000 women-years at risk [7] with a sensitivity of
71–92 % and a specificity of 79–86 % [8, 9]. However,
breast MRI is costly and limited in women with claustro-
phobia, obese patients and patients with renal failure [10].
In addition, in the clinical setting MRI shows a relatively
low specificity and positive predictive value [11] leading to
a high rate of unnecessary biopsies. In the last few years,
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molecular breast imaging (MBI), also called breast-specific
c-imaging (BSGI), has been introduced as an adjunct
modality in BC detection. MBI is a functional tool based
on the use of 99mTc-sestamibi as tumour tracer [12].
Recently, a 99mTc-sestamibi MBI-guided biopsy system
has been developed, applicable in patients with suspicious
breast lesions on MBI (BI-RADS criteria 4–5), which are
occult or unclear on MG/US [13]. We performed a search
of the literature in PubMed/MEDLINE database using
‘‘99mTc-sestamibi’’ AND ‘‘biopsy’’ AND ‘‘breast cancer’’
as keywords. The search was restricted to English lan-
guage. The references of the retrieved articles were
examined to identify additional articles. The aim of this
review is to discuss the methodological aspects of this
novel radioguided-biopsy method, including its advan-
tages, limitations and future clinical applications.
99mTc-sestamibi MBI technique and interpretation
Increased uptake of 99mTc-sestamibi in breast cancer cells
is based on increased vascularity and cytoplasmic mito-
chondrial density and activity [14, 15]. However, overex-
pression of multidrug resistance membrane proteins (Pgp
and MRP1) and anti-apoptotic Bcl-2 protein of the outer
mitochondrial membrane can limit retention of 99mTc-
sestamibi in tumour cells [16]. In 2002, the first study
described the performance of this functional breast-dedi-
cated modality in patients with breast tumours [17]. Since
then, MBI has been validated in several studies [18]. In
screening studies in women with dense breasts and
increased BC risk, the addition of MBI to MG significantly
increased sensitivity to 91 % with a detection rate of 11–12
per 1000 screened women [19, 20]. A recent meta-analysis,
including 19 studies, showed that MBI has a sensitivity of
95 % and specificity of 80 % in detecting BC. Addition-
ally, the authors reported that MBI detected MG-occult
breast lesions in 4 % and additional lesions in 6 % of
patients with suspicious MG or proven breast lesions [18].
99mTc-sestamibi-MBI refers to functional imaging of the
breast using a breast-dedicated high-resolution, small field
of view (FOV) gamma camera; the images, based on the
detection of increased uptake of 99mTc-sestamibi in the
tumour in comparison to normal tissue, are independent of
breast density. The original MBI system still employs a
single detector with a 20 9 15 cm FOV, containing an
array of sodium iodide (NaI) crystals (3 9 3 mm pixel
size) coupled to position sensitive photomultiplier tubes
(PSPMTs). Most literature reports have been based on the
use of a single-head system (Dilon 6800, Dilon Tech-
nologies, Newport News, VA). In recent years, dual-head
detection became available following the introduction of
the MBI devices Discovery NM750b (GE Healthcare,
Milwaukee, WI) and LumaGem 3200 s (Gamma Medica,
Inc., Northridge, CA) which employ two opposite cad-
mium-zinc-telluride (CZT) detectors with small FOV
(24 9 16 resp. 20 9 16 cm) and 2.5 resp. 1.6 mm pixel
size; these devices are aimed to provide better energy
resolution [21]. A summary of the commercially available
MBI devices is shown in Table 1.
In both single-head and dual-head MBI devices, the
patient is seated during the entire study and the breast is
positioned directly on the detector(s) with light compression
to limit patient motion. Patients receive an intravenous
injection of the radiotracer (600–800 MBq 99mTc-sestamibi
for single-head MBI or 300 MBq for dual-head MBI-sys-
tems) in an antecubital vein contralateral to the breast lesion.
Approximately 5–10 min after the injection of the radio-
tracer, standard planar images are performed for each breast
in the craniocaudal (CC) and mediolateral oblique (MLO)
projections. The acquisition time for each image is 8–10 min
with a total acquisition time of approximately 40 min per
study. If needed, additional images may be acquired
(lateromedial or mediolateral view, anteroposterior view
(axilla) or axillary craniocaudal view). These projections
correspond to the standard projections used in MG (Fig. 1).
For interpretation of the images a viewing system should be
available which enables the adjustment of the image contrast
and simultaneous display of the mammographic and scinti-
graphic images. The scintigraphic images are interpreted
according to a functional BI-RADS classification, based on
the guidelines of the Society of Nuclear Medicine (SNM) as
shown in Table 2 and Fig. 2 [12]. Recently, a lexicon for the
description of MBI images has been developed [22], based
on familiar radiological BI-RADS lexicon terminology, as
well as on the proposed BI-RADS-type lexicon for positron
emission mammography (PEM).
99mTc-sestamibi MBI-guided biopsy procedure
MBI-guided biopsy procedure is based on both preoperative
imaging and intraoperative excision using 99mTc-sestamibi
as radiotracer for target tissue localization, according to the
radioguided surgery concept [23]. To date, methodological
aspects of PEM-guided biopsy using 18F-fluorodeoxyglu-
cose (FDG) have been described [24], whereas no article has
yet been reported the steps in MBI-guided breast biopsy
using 99mTc-sestamibi. For this latter modality, slant-hole
collimator technology (GammaLo¯c MBI localization sys-
tem, Dilon Technologies, Newport News, VA) is used to
calculate the lesion depth using a single-head system [13].
Biopsy is performed with the patient in seated position. The
breast is placed between the detector and the paddle (Cor-
reLocatorTM, Dilon Technologies, US) with light compres-
sion to reduce patient motion. A fiducial source using
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Cerium-139 (139Ce) is imbedded into the compression pad-
dle as spatial reference point for determining the position of
the lesion. The patient is administered with approximately
600 MBq of 99mTc-sestamibi into an arm vein contralateral
to the breast lesion. Approximately 5 min after the injection,
a scout image is performed using a parallel-hole collimator
for positioning of the lesion. The breast lesion is in the exact
position when it is assumed to be visible in the FOV of both
the left and right stereotactic views. Subsequently, left and
right stereotactic images are performed using a sliding slant-
hole collimator (StereoViewTM, Dilon Technologies, US)
for determining the grid localization (X, Y) and the depth
(Z) of the lesion. Using this slant-hole collimator, 20 degree
angle stereo views are required from both the left and right
side (Fig. 3: Step 1). The location and the depth are clearly
identified at the point where the angles intersect. Subse-
quently, the software (GammaLo¯c, Dilon Technologies,
US) calculates the X, Y, Z coordinates indicating the X and Y
coordinates in the grid and the depth of the trocar needle in
the guidance block (Fig. 3: Step 2). After injection of local
anesthetic, the guidance block is placed in the paddle in the
correct position. After the trocar needle is introduced into the
sheath and the depth marker is set in the right position, the
trocar needle is placed into the breast (Fig. 3: Step 3). Sub-
sequently, a first image (pre-verification) is acquired in the
energy window of 99mTc with the needle in place. After-
wards, the trocar needle is removed and replaced by a
radioactive 139Ce source followed by a second image (post-
verification) using the energy window of 139Ce. Both pre-
and post-verification images are acquired using both slant-
hole collimators located under the lesion to verify the correct
position of the needle (Fig. 3: Step 4). After this verification
step, the actual biopsy is performed using a vacuum-assisted
device (VAD). The VAD is composed of a large bore needle
with an internal cutting trocar that rotates 360 degree around
the axis of the needle cutting 6 specimens from the target
lesion, which is vacuum aspirated into the sampling cham-
ber. A radiological marker is left behind at the biopsy site to
enable further lesion excision or follow-up. Tissue sample
activity is measured ex vivo using the parallel-hole colli-
mator, followed by histopathological analysis. Finally, MG
is performed to verify the correct marker position (Fig. 3:
Step 5).
99mTc-sestamibi MBI-guided biopsy in comparison
with MG, US and MRI-guided biopsy
In recent years, percutaneous image-guided breast biopsy
has gained importance as an alternative to surgical biopsy,
mainly using sonographic, stereotactic, or MRI guidance.
US-guided biopsy is the first technique of choice for
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Fig. 1 Mammography and MBI in a 47-year old female with dense
breasts. Mammography showed no abnormalities (BI-RADS I) in
right (a) and left (b) craniocaudal views and in right (c) and left
(d) mediolateral oblique images. MBI showed suspicious uptake (BI-
RADS V) in right craniocaudal (e), lateral-oblique (g) and additional
lateral views (i). Histopathological examination revealed invasive
adenocarcinoma
Table 2 BI-RADS classification and MBI interpretation criteria according to SNM [12]
BI-RADS MBI-interpretation
1-Negative Homogeneous uptake
2-Benign Patchy or diffusely increased uptake, often bilateral and correlating with MG anatomy
3-Probably benign Multiple patchy areas of uptake, mild to moderate intensity




5-Highly suggestive of malignancy Moderate to intense focal uptake with well-delineated contours
BI-RADS breast imaging-reporting and data system, MBI molecular breast imaging
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behind the lesion to be biopsied and the verification of the
correct needle placement is real-time. The main advantages
of US-guided biopsy are its wide availability, lack of
ionizing radiation and low costs [25]. Stereotactic biopsy is
usually performed for sampling micro-calcifications and
distortions not detected on US [26]. The patient is in
upright or prone position and in both situations with
compression of the breast [27, 28]. The prone position
results in higher comfort for the patient, decreased likeli-
hood of patient motion and less vasovagal reactions [29].
MRI-guided biopsy is principally performed when the
breast lesion is occult both on US and MG [30]. The patient
is in prone position with the breast located in a dedicated
biopsy coil with compression in the mediolateral direction.
The procedure time for MRI-guided biopsy is approxi-
mately 30–70 min [31, 32]. MRI-guided biopsy poses
several challenges, such as the necessity to remove the
patient from the magnet to perform the biopsy and the
transient nature of the contrast enhancement. Furthermore,
the access to the medial and posterior breast tissue is
limited. An important limitation concerns the inability to
verify the successful sampling of the target lesion, since
tissue samples do not enhance ex vivo [33, 34]. As men-
tioned earlier, MBI is increasingly being used as adjunct
modality to MG and US for detecting BC. In contrast to
MG, MBI is a functional imaging technique that is not
influenced by breast density and architectural distortion,
regularly leading to the discovery of MG occult breast
malignancies [18, 35]. For patients with occult or unclear
breast lesions on MG/US but suspicious MBI, the possi-
bility to use MBI-guided biopsy appears to be an excellent
alternative to acquire representative tissue samples for
histopathological analysis. To date, several MBI-guided
biopsy methods have been described in the literature. In
2004, Coover et al. reported on a method to localise the
lesion using a dedicated breast camera with an open biopsy
paddle. The site of the lesion was identified using 57Co
point source on the breast and the camera monitor in the
persistent mode. Subsequently, two localization needles
were placed into the site of the lesion followed by an open
Fig. 2 Examples of MBI according to BI-RADS classification [12]
displayed together with corresponding mammography. Left cranio-
caudal view (a) showing homogeneous uptake (BI-RADS I); left
craniocaudal view (b) showing diffusely increased uptake (BI-RADS
II); right craniocaudal view (c) showing multiple patchy areas of
uptake (BI-RADS III) pointed by arrows; right craniocaudal view
(d) showing small focal area of increased uptake (BI-RADS IV,
arrow); right craniocaudal (e) showing intense uptake (BI-RADS V,
arrow)
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Fig. 3 Procedure steps of 99mTc-Sestamibi MBI-guided biopsy using a stereotactic localization system (GammaLoc)
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biopsy of the area where the two needles intersected. The
authors reported a suspicious finding in 5 of 37 patients
(13.7 %) with dense breasts and at high risk of breast
cancer; biopsy revealed carcinoma in 3 out of 5 of these
patients [36]. In 2006, Welch et al. reported on the
development of a compact dedicated breast camera-guided
Fig. 3 continued
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stereotactic breast biopsy system. A fiducial marker con-
taining 0.925 MBq of 57Co was mounted inside the top of
the breast compression paddle as spatial reference point.
An algorithm for determining the spatial location of the
breast lesion was implemented in the software of the
dedicated breast camera [37]. More recently, Weinmann
et al. developed a conical slant hole (CSH) collimator for
MBI-guided biopsy with dual-head CZT, improving the
accuracy of lesion depth determination [38]. To our
knowledge, no full studies have yet been reported on
clinical validation of MBI-guided biopsy procedures.
Based on our own clinical experience, the stereotactic
biopsy method using the slant-hole collimator localization
system as described here shows good patient acceptability.
The procedure time is approximately 75 min, which is
longer than the MG/US guided methods. The difference is
mainly explained by the prolonged image acquisition
which is necessary to accurately display lesion uptake of
99mTc-sestamibi for subsequent stereotactic localization
and biopsy (Fig. 4). However, procedure time is compa-
rable to MRI guided biopsy. Complications are similar to
those in other radiological biopsy methods such as syn-
cope, hematoma formation and marker migration. Table 3
describes the clinical indications for MBI-guided biopsy.
This biopsy method using 99mTc-sestamibi is considered a
complementary modality to MG/US-guided biopsy and an
alternative to MRI-guided biopsy. It is principally indicated
in patients with occult lesions on MG/US but suspicious on
MBI (BI-RADS criteria 4–5) and occult after second-look
US. Other possible indications include: (i) unclear lesions
on MG/US but suspicious on MBI (BI-RADS criteria 4–5);
(ii) failure of other biopsy methods. A potential future
indication concerns optimization of primary tumour tissue
sampling in patients with locally advanced breast cancer
(LABC) by means of 99mTc-sestamibi-guided targeted
biopsy. In the literature non-correspondence between the
core biopsy location and the area with highest metabolic
activity in the tumour has been described for stage II/III
breast cancer patients scheduled for neoadjuvant
chemotherapy [39]. Since early and increased concentra-
tion of 99mTc-sestamibi in breast carcinomas is associated
Fig. 4 Procedure time of the different steps in 99mTc-sestamibi MBI-
guided biopsy
Table 3 Indications for MBI-guided biopsy in clinical practice
Indication for MBI-guided biopsy
Occult lesions on MG/US but MBI-suspiciousa and occult after
second look US
Unclear lesions on MG/US but MBI-suspiciousa
Failure of earlier radiological biopsy
Future: targeted biopsy of large heterogeneous tumours in patients
with locally advanced breast cancer
MG mammography, US ultrasound, MBI molecular breast imaging
a BI-RADS criteria 4 and 5
Table 4 Comparison of image-guided biopsy modalities
Biopsy method Compression Patient position Advantages Limitations
US-guided No Supine Real time verification of needle
position, fast, no ionizing radiation,
low costs
Not useful for MC/distortions
Stereotactic Yes Upright/prone Useful for MC/distortions, sample
verification ex vivo possible (MC)
Ionizing radiation
MRI-guided Yes Prone Useful for US and MG occult lesions,
no ionizing radiation
High costs, long procedure time,
limitation in claustrophobia, obesity and
renal insufficiently, sample verification
ex vivo not possible
MBI-guided Yes (mild) Upright Useful for indeterminate/unclear
lesions on MG/US, sample
verification ex vivo possible
Lesions close to the pectoral muscle,
ionizing radiation, long procedure time
US ultrasound, MRI magnetic resonance imaging, MG mammography, MBI molecular breast imaging, MC microcalcifications
374 Clin Transl Imaging (2016) 4:367–376
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with high proliferation rate, indicating more aggressive
tumour behaviour [40], the sampling of the most prolifer-
ative parts of the tumour that correspond with highest
uptake of 99mTc-sestamibi in large heterogeneous tumours
could result in more optimal therapy planning in patients
with LABC. The advantages and disadvantages of the
different biopsy methods are summarized in Table 4. The
main advantage of MBI-guided biopsy compared to MRI-
guided biopsy is the possibility to measure radioactivity of
the tissue samples ex vivo, in this way verifying that the
target lesion has been sampled successfully. However,
biopsy may be difficult in lesions close to the pectoral
muscle because they may not be completely visualized due
to the vertical position of the patient in relation to the field
of view of the camera.
In conclusion, MBI-guided biopsy represents an adju-
vant tool to MG/US-guided biopsy and a promising alter-
native to MRI-guided biopsy. The principal application of
this new biopsy method is in patients with occult or unclear
lesions on MG and US that are suspicious on MBI (BI-
RADS criteria 4 and 5). The future indication is in targeted
biopsies in patients with large heterogeneous tumours.
Further studies are needed to define the accuracy of this
biopsy procedure.
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